Clinical Trial Update: Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combined chemo-immunotherapy plus SBRT as neoadjuvant treatment for luminal (HR+/HER2-) breast cancer; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: HR+/HER2- Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING